Recent advancement of HDAC inhibitors against breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12032-023-02058-x.pdf
Reference162 articles.
1. Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, et al. Breast cancer drug approvals issued by EMA: a review of clinical trials. Cancers. 2021;13:5198. https://doi.org/10.3390/cancers13205198.
2. Zolota V, Tzelepi V, Piperigkou Z, Kourea H, Papakonstantinou E, Argentou MI, Karamanos NK. Epigenetic alterations in triple-negative breast cancer—the critical role of extracellular matrix. Cancers. 2021;13:713. https://doi.org/10.3390/cancers13040713.
3. Yoshida M, Kudo N, Kosono S, Ito A. Chemical and structural biology of protein lysine deacetylases. Proc Jpn Acad Ser B. 2017;93:297–321. https://doi.org/10.2183/pjab.93.019.
4. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349–52. https://doi.org/10.1038/38664.
5. Jenke R, Reßing N, Hansen F, Aigner A, Büch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13:634. https://doi.org/10.3390/cancers13040634.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents;In Silico Pharmacology;2024-09-14
2. Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy;European Journal of Pharmacology;2024-09
3. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment;Pharmacological Research;2024-06
4. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells;Cancers;2024-04-29
5. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3